The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Injectable Paromomycin for Visceral Leishmaniasis in India
Abstract
BACKGROUND: Visceral leishmaniasis (kala-azar) affects large, rural, resource-poor populations in South Asia, Africa, and Brazil. Safe, effective, and affordable new therapies are needed. We conducted a randomized, controlled, phase 3 open-label study comparing paromomycin, an aminoglycoside, with amphotericin B, the present standard of care in Bihar, India. METHODS: In four treatment centers for visceral leishmaniasis, 667 patients between 5 and 55 years of age who were negative for the human immunodeficiency virus and had parasitologically confirmed visceral leishmaniasis were randomly assigned in a 3:1 ratio to receive paromomycin (502 patients) at a dose of 11 mg per kilogram of body weight intramuscularly daily for 21 days or amphotericin B (165 patients) at a dose of 1 mg per kilogram intravenously every other day for 30 days. Final cure was assessed 6 months after the end of treatment; safety assessments included daily clinical evaluations and weekly laboratory and audiometric evaluations. Noninferiority testing was used to compare 6-month cure rates, with a chosen margin of noninferiority of 10 percentage points. RESULTS: Paromomycin was shown to be noninferior to amphotericin B (final cure rate, 94.6% vs. 98.8%; difference, 4.2 percentage points; upper bound of the 97.5% confidence interval, 6.9; P<0.001). Mortality rates in the two groups were less than 1%. Adverse events, which were more common among patients receiving paromomycin than among those receiving amphotericin B (6% vs. 2%, P=0.02), included transient elevation of aspartate aminotransferase levels (>3 times the upper limit of the normal range); transient reversible ototoxicity (2% vs. 0, P=0.20); and injection-site pain (55% vs. 0, P<0.001); and in patients receiving amphotericin B, as compared with those receiving paromomycin, nephrotoxicity (4% vs. 0, P<0.001), fevers (57% vs. 3%), rigors (24% vs. 0, P<0.001), and vomiting (10% vs. <1%, P<0.001). CONCLUSIONS: Paromomycin was shown to be noninferior to amphotericin B for the treatment of visceral leishmaniasis in India. (ClinicalTrials.gov number, NCT00216346.)
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Leishmaniasis: current situation and new perspectives
Desjeux, P. (2004) · Comparative Immunology, Microbiology and Infectious Diseases · doi:10.1016/j.cimid.2004.03.004 · Cited by 2,322
Walsh, T. J., Pappas, P., Winston, D. J., Lazarus, H. M., Petersen, F., Raffalli, J., Yanovich, S., Stiff, P., Greenberg, R., Donowitz, G., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejm200201243460403 · Cited by 979
Oral Miltefosine for Indian Visceral Leishmaniasis
Sundar, S., Jha, T. K., Thakur, C. P., Engel, J., Sindermann, H., Fischer, C., Junge, K., Bryceson, A., & Berman, J. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa021556 · Cited by 779
Self-citationSundar, S., More, D. K., Singh, M. K., Singh, V. P., Sharma, S., Makharia, A., Kumar, P. C. K., & Murray, H. W. (2000) · Clinical Infectious Diseases · doi:10.1086/318121 · Cited by 664
Self-citationMiltefosine, an Oral Agent, for the Treatment of Indian Visceral Leishmaniasis
Jha, T. K., Sundar, S., Thakur, C. P., Bachmann, P., Karbwang, J., Fischer, C., Voss, A., & Berman, J. (1999) · New England Journal of Medicine · doi:10.1056/nejm199912093412403 · Cited by 468
Self-citationWingard, J. R., Kubilis, P., Lee, L., Yee, G., White, M., Louise, W., Bowden, R., Anaissie, E., Hiemenz, J., & Lister, J. (1999) · Clinical Infectious Diseases · doi:10.1086/313498 · Cited by 368
Collin, S., Davidson, R., Ritmeijer, K., Keus, K., Melaku, Y., Kipngetich, S., & Davies, C. (2004) · Clinical Infectious Diseases · doi:10.1086/381203 · Cited by 180
Chunge, C. N., Owate, J., Pamba, H. O., & Donno, L. (1990) · Transactions of the Royal Society of Tropical Medicine and Hygiene · doi:10.1016/0035-9203(90)90263-e · Cited by 175
Jha, T. K., Olliaro, P., Thakur, C. P. N., Kanyok, T. P., Singhania, B. L., Singh, I. J., Singh, N. K. P., Akhoury, S., Jha, S., & Lockwood, D. N. J. (1998) · BMJ · doi:10.1136/bmj.316.7139.1200 · Cited by 170
Self-citationAdvances in the treatment of leishmaniasis
Sundar, S., & Rai, M. (2002) · Current Opinion in Infectious Diseases · doi:10.1097/00001432-200212000-00007 · Cited by 153
Self-citation
Cited by
Drug Resistance in Leishmaniasis
Croft, S. L., Sundar, S., & Fairlamb, A. H. (2006) · Clinical Microbiology Reviews · doi:10.1128/cmr.19.1.111-126.2006 · Cited by 1,663
Self-citationVisceral leishmaniasis: what are the needs for diagnosis, treatment and control?
Chappuis, F., Sundar, S., Hailu, A., Ghalib, H., Rijal, S., Peeling, R. W., Alvar, J., & Boelaert, M. (2007) · Nature Reviews Microbiology · doi:10.1038/nrmicro1748 · Cited by 1,490
Self-citationKrause, K. M., Serio, A. W., Kane, T. R., & Connolly, L. E. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a027029 · Cited by 1,149
Natural products to drugs: natural product-derived compounds in clinical trials
Butler, M. S. (2008) · Natural Product Reports · doi:10.1039/b514294f · Cited by 1,075
The Relationship between Leishmaniasis and AIDS: the Second 10 Years
Alvar, J., Aparicio, P., Aseffa, A., Den Boer, M., Cañavate, C., Dedet, J.-P., Gradoni, L., Ter Horst, R., López-Vélez, R., & Moreno, J. (2008) · Clinical Microbiology Reviews · doi:10.1128/cmr.00061-07 · Cited by 937
Natural products: An evolving role in future drug discovery
Mishra, B. B., & Tiwari, V. K. (2011) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2011.07.057 · Cited by 860
Kinetoplastids: related protozoan pathogens, different diseases
Stuart, K., Brun, R., Croft, S., Fairlamb, A., Gürtler, R. E., McKerrow, J., Reed, S., & Tarleton, R. (2008) · Journal of Clinical Investigation · doi:10.1172/jci33945 · Cited by 604
Aronson, N., Herwaldt, B. L., Libman, M., Pearson, R., Lopez-Velez, R., Weina, P., Carvalho, E. M., Ephros, M., Jeronimo, S., & Magill, A. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/ciw670 · Cited by 458
Single-Dose Liposomal Amphotericin B for Visceral Leishmaniasis in India
Sundar, S., Chakravarty, J., Agarwal, D., Rai, M., & Murray, H. W. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0903627 · Cited by 434
Self-citationLeishmaniasis chemotherapy—challenges and opportunities
Croft, S. L., & Olliaro, P. (2011) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2011.03630.x · Cited by 424
Use of Antimony in the Treatment of Leishmaniasis: Current Status and Future Directions
Haldar, A. K., Sen, P., & Roy, S. (2011) · Molecular Biology International · doi:10.4061/2011/571242 · Cited by 408
Recent Developments in Drug Discovery for Leishmaniasis and Human African Trypanosomiasis
Nagle, A. S., Khare, S., Kumar, A. B., Supek, F., Buchynskyy, A., Mathison, C. J. N., Chennamaneni, N. K., Pendem, N., Buckner, F. S., Gelb, M. H., et al. (2014) · Chemical Reviews · doi:10.1021/cr500365f · Cited by 348
Recent advances in leishmaniasis treatment
Tiuman, T. S., Santos, A. O., Ueda-Nakamura, T., Filho, B. P. D., & Nakamura, C. V. (2011) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2011.03.021 · Cited by 345
Sundar, S., Sinha, P. K., Rai, M., Verma, D. K., Nawin, K., Alam, S., Chakravarty, J., Vaillant, M., Verma, N., Pandey, K., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(10)62050-8 · Cited by 337
Self-citationMechanism of Amphotericin B Resistance in Clinical Isolates of Leishmania donovani
Purkait, B., Kumar, A., Nandi, N., Sardar, A. H., Das, S., Kumar, S., Pandey, K., Ravidas, V., Kumar, M., De, T., et al. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00030-11 · Cited by 324
An update on pharmacotherapy for leishmaniasis
Sundar, S., & Chakravarty, J. (2015) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2015.973850 · Cited by 320
Self-citationManagement of trypanosomiasis and leishmaniasis
Barrett, M. P., & Croft, S. L. (2012) · British Medical Bulletin · doi:10.1093/bmb/lds031 · Cited by 304
New developments in aminoglycoside therapy and ototoxicity
Xie, J., Talaska, A. E., & Schacht, J. (2011) · Hearing Research · doi:10.1016/j.heares.2011.05.008 · Cited by 287
Drug resistance in leishmaniasis
Chakravarty, J., & Sundar, S. (2010) · Journal of Global Infectious Diseases · doi:10.4103/0974-777x.62887 · Cited by 270
Self-citationCarbohydrate-based drugs launched during 2000−2021
Cao, X., Du, X., Jiao, H., An, Q., Chen, R., Fang, P., Wang, J., & Yu, B. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.05.020 · Cited by 267
Leishmaniasis: an update of current pharmacotherapy
Sundar, S., & Chakravarty, J. (2013) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2013.755515 · Cited by 261
Self-citationChemotherapy of leishmaniasis: present challenges
ULIANA, S. R. B., TRINCONI, C. T., & COELHO, A. C. (2018) · Parasitology · doi:10.1017/s0031182016002523 · Cited by 261
Recent advances and new strategies on leishmaniasis treatment
Roatt, B. M., de Oliveira Cardoso, J. M., De Brito, R. C. F., Coura-Vital, W., de Oliveira Aguiar-Soares, R. D., & Reis, A. B. (2020) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-020-10856-w · Cited by 253
Liposomal amphotericin B and leishmaniasis: Dose and response
Sundar, S., & Chakravarty, J. (2010) · Journal of Global Infectious Diseases · doi:10.4103/0974-777x.62886 · Cited by 217
Self-citationMultiple deadlocks in the development of nonprofit drugs
Cvek, B. (2022) · Drug Discovery Today · doi:10.1016/j.drudis.2022.06.001 · Cited by 5
Metadata
- Authors
- Sundar, S., Jha, T. K., Thakur, C. P., Sinha, P. K., & Bhattacharya, S. K.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2007-06-21
- Volume
- 356
- Issue
- 25
- Pages
- 2571-2581
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2103921559
- Cited by
- 471
- References
- 13
- FWCI
- 35.53
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.